Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome

Am J Ophthalmol. 1998 Oct;126(4):600-2. doi: 10.1016/s0002-9394(98)00129-9.


Purpose: To determine if latanoprost reduces intraocular pressure in eyes with glaucoma associated with Sturge-Weber syndrome.

Methods: We conducted a prospective study in which eyes with uncontrolled intraocular pressure associated with Sturge-Weber syndrome were treated with latanoprost 0.005% once daily. All eyes were already receiving at least two other antiglaucoma medications. Intraocular pressure was measured at baseline and after treatment for at least 1 month. All intraocular pressure measurements were taken within 24 hours of drug instillation.

Results: Six eyes of six patients received latanoprost. Two (28%) of the six eyes demonstrated an intraocular pressure decrease that averaged 8.8 mm Hg. These two responders had juvenile onset glaucoma, whereas the four nonresponders had congenital onset glaucoma.

Conclusions: Latanoprost may significantly reduce intraocular pressure in selected patients with glaucoma associated with Sturge-Weber syndrome.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Glaucoma / drug therapy*
  • Glaucoma / etiology
  • Humans
  • Intraocular Pressure / drug effects
  • Klippel-Trenaunay-Weber Syndrome / complications*
  • Latanoprost
  • Ophthalmic Solutions
  • Prospective Studies
  • Prostaglandins F, Synthetic / therapeutic use*
  • Sturge-Weber Syndrome / complications*


  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic
  • Latanoprost